A Study of Telitacicept for IgA Nephropathy (TELIGAN)
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Telitacicept in Patients With Primary IgA Nephropathy
Sponsor: RemeGen Co., Ltd.
Listed as NCT05799287, this PHASE3 trial focuses on Primary IgA Nephropathy and remains ongoing. Sponsored by RemeGen Co., Ltd., it has been updated 9 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE3
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE3
-
Nov 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE3
-
Oct 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2023 — Oct 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Apr 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- RemeGen Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baoding, China , Baotou, China , Beijing, China , Bengbu, China , Cangzhou, China , Changchun, China , Changsha, China , Changzhou, China , Chengdu, China , Chongqing, China and 46 more locations